The DNA test that can tell if prostate cancer will return in patients who have suffered the disease
- New test of genetic 'signature' had an 80 per cent success rate in a trial
- One-third to half of prostate cancer patients face disease spreading
- Prostate cancer is the most common cancer in British men
Breakthrough: The test, which had an 80 per cent success rate in trials, looks for a genetic 'signature that is linked to a high risk of cancer coming back
Scientists are developing a test to predict which prostate cancer patients are most likely to suffer a recurrence of the disease.
It means doctors will be able to give those at high risk drugs to improve their chances.
Men who have a low risk of the disease coming back after surgery and radiotherapy will be spared additional treatment.
The new test, which had an 80 per cent success rate in a trial, looks for a genetic ‘signature’, or pattern, that is linked to a high risk of cancer coming back.
The Canadian researchers will release details of their work today at a conference of the European Society for Radiotherapy and Oncology in Vienna.
Professor Robert Bristow said between one-third and half of patients face a spread of cancer outside the prostate gland that is not detected in initial treatment.
He said: ‘Men who fail treatment within two years may be at the highest risk of dying from their prostate cancer.
‘New tests are required that are better at predicting which patients will have cancer recur.
‘These men can then be offered additional treatments, such as chemotherapy and hormone therapy, that will combat the prostate cancer throughout their entire body . . . in order to improve their chances of survival.’
Prostate cancer is the most common cancer in men. In the UK, more than 41,000 men are diagnosed each year, leading to around 10,000 deaths annually.
The new genetic test was developed by Professor Bristow, of the University of Toronto, and Dr Paul Boutros, of the Ontario Institute of Cancer Research.
By analysing the DNA in tissue taken from a tumour before any treatment, it can predict whether surgery and radiotherapy will be successful for that patient.
Professor Bristow said: ‘This is the first report of a test using this information derived from biopsy samples that can predict with close to 80 per cent accuracy which men are at high or low risk of prostate cancer recurring.’
The researchers plan further trials over the next two years to ensure it will work in hospitals.
‘If all goes well, this will lead to a new test for cancer patients that can be turned around in three days and will tell doctors which patients will do well with local treatment alone – surgery or radiotherapy – and which will need extra treatment,’ he said.
Tumour: Doctors are keen to discover which cancer patients are likely to respond well to treatment
The researchers analysed DNA from 126 patients thought to be at intermediate risk, and followed their progress for eight years.
They analysed each patient’s whole genome to identify areas with missing, extra, or irregular sections of genetic material.
They found a pattern, or genetic signature, that is common to men at high risk of cancer recurring.
They tested their findings on 150 further patients, with similar results. Professor Bristow said: ‘These results will enable us to develop a new way of personalising medicine.’
█ A prostate cancer treatment called brachytherapy, in which low-dose radioactive seeds are placed inside the prostate, could help half of men to retain their sex lives after treatment.
Research shows this internal radiation is better than conventional radiotherapy, in which only one-third of men have their sexual function unaffected.
It should be offered to all patients, said researcher Dr Renee Oismuller.
- SHOCKING video of alligator that tucks into an electric eel
- Girl in bikini gets tasered to raise money for charity
- Shocking video shows youths swinging an elderly woman around
- WARNING GRAPHIC: Usain Bolt 'daggers' a girl in Trinidad
- Breathtaking rare footage of tigers running at full speed
- Father posts hilarious Vines Of his Saturday mornings
- Pulse signal heard from depths of Indian Ocean
- Crazy cat fight caught on collar mounted camera
- Ship looking for MH370 detects black box 'pulse signal'
- Delight on young girl's face as cochlear implant is turned...
- Train rumbles through the middle of busy Asian market
- Thar she BLOWS! Donna Pascoe reels in 64 stone tuna fish
- Chinese ship looking for missing Malaysia Airlines plane...
- Might of US Navy races to save ONE-YEAR-OLD baby after...
- Miami woman arrested for KILLING animals while performing...
- Losing our religion: New research shows the Internet could...
- Get out of the way, ma'am: Derek Jeter fends off greedy...
- Drunken Mormon woman, 20, froze to death after she and a...
- Bride with terminal bone cancer has 'dream wedding' while...
- Here's what happens when an alligator tries to eat an...
- Microsoft launches updated FREE version of Office online to...
- Security fears at Buckingham Palace after Queen's Guard...
- A FOURTH student comes forward with allegations Math...
- CIA official dies in apparent suicide
Val, Wales, 1 day ago
I was diagnosed as having prostate cancer a couple of years ago following a biopsy. Prostate cancer can be very aggressive or not aggressive, in my case it is of the not aggressive type. I decided to go for the 'watchful waiting' option where I have a PSA test every three months and two appointments a year with the urology team. Last year my PSA rose quickly and in December I had another biopsy that showed NO cancer. Since then I have had another PSA test that shows the PSA dropping back. This experience reveals what urologists will admit is the hit-and-miss methods of basing decisions on the possibility of cancer from the PSA test. It can give both false positive and false negative results. The biopsy is also not definitive. I do have cancer, it was found in my first biopsy but was missed with the second. It hasn't spread even though the PSA had shot up (and then dropped back). I am very grateful to the NHS and hope that more money can be found for research.
Trinket, Stockport, United Kingdom, 11 hours ago
Val, Wales, 8 hours ago